Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | ANCHOR: melflufen in R/R MM

Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, explains the latest findings of the Phase I/II ANCHOR study NCT03481556): melphalan flufenamide (melflufen) plus dexamethasone, and daratumumab or bortezomib treatment in relapsed/refractory multiple myeloma. Melflufen is a first-in-class peptide-drug conjugate that enables alkylating agents to be released directly into tumor cells. Both arms show encouraging clinical activity and good tolerability. The DARA arm contained more patients, with longer follow up, suggesting consistent responses with continued therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.